Clinical Trial Update: Safety Study of High Dose Temozolomide to Treat Relapsed/Refractory Central Nervous System (CNS) Malignancy [Phase 1]

View source ↗

Summary

Phase 1 safety study of high-dose temozolomide in relapsed or refractory central nervous system malignancies has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Central Nervous System Neoplasms
• Neoplasms

Drugs mentioned

• Temodar (Temozolomide)

Snippet

Sponsor: Tufts Medical Center | Conditions: Central Nervous System Neoplasms, Neoplasm Metastasis | Phase 1 | Status: TERMINATED